聚乙二醇化药物免疫原性的研究进展  

Research progress on immunogenicity of PEGylated drugs

作　　者：潘永红 张玉凤 唐海玲 PAN Yong-hong;ZHANG Yu-feng;TANG Hai-ling(The People's Hospital of Jimo.Qingdao,Qingdao SHANDONG 266228,China;Guangxi University of Chinese Medicine,Nanning GUANGXI 530200,China)

机构地区：[1]青岛市即墨区人民医院,山东青岛266228 [2]广西中医药大学,广西南宁530200

出　　处：《中国新药与临床杂志》2024年第10期736-742,共7页Chinese Journal of New Drugs and Clinical Remedies

基　　金：广西中医药大学校级博士课题科研启动基金(2019BS010);广西中医药大学自然科学研究面上项目(2020MS002);广西高校中青年教师科研基础能力提升项目(2020KY0747)。

摘　　要：利用聚乙二醇(PEG)修饰药物或纳米药物载体是目前被广泛接受的可有效提高药物体内治疗效果的方法,但PEG化药物多具有体内免疫原性。PEG化药物通过胸腺依赖或非胸腺依赖途径引发抗PEG免疫球蛋白IgG和IgM的分泌,导致药物在血液中的清除效率显著增高并引发超敏反应。PEG分子、药物或药物载体的理化特性会影响抗PEG抗体的分泌,PEG化修饰密度、给药频率等也会影响PEG化药物的免疫原性。优化PEG化药物免疫原性的产生原因及影响因素是改善其体内免疫原性的有效方法,PEG可替代生物材料是药物研发的新方向。The use of polyethylene glycol(PEG)modified drugs or nano-carriers is a widely accepted method that can effectively improve therapeutic effects of drugs in vivo.However,PEGylated drugs are usually immunogenic in vivo and can trigger the secretion of anti-PEG immunoglobulin IgG and IgM,leading to a significant increase in blood clearance efficiency of drugs and the occurrence of hypersensitivity reactions.The physicochemical properties of PEG molecules,drugs,or drug carriers will affect the secretion of anti-PEG antibodies,and the PEG modification density and administration frequency will also affect the immunogenicity of PEGylated drugs.Optimizing the causes and influencing factors is an effective method to improve the immunogenicity of PEGylated drugs in vivo.PEG alternative biomaterial is a new direction of drug research and development.

关 键 词：聚乙二醇 免疫原性 生物药学 纳米药物 PEG化药物 抗PEG抗体 

分 类 号：R967[医药卫生—药理学] R979[医药卫生—药学]